Novartis Ag

Rene Lattmann

Claudia Betschart

Junichi Sakaki

Martin Missbach

Naoki Teno

Nikolaus Johannes Stiefl

Lv Liao

Thomas Ullrich

Eva Altmann

Sven Weiler

Genji Iwasaki

Kenji Hayakawa

Luca Arista

Osamu Irie

Xiaoyang Wang

Rita Ramos

Peggy Usselmann

Dimitrios Lizos

Tingying Zhu

Yizong Zhou

Yubo Zhang

Sreehari Babu

Liladhar Murlidhar Waykole

Kai Cui

Jianwei Bian

Jialiang Li

John Henry Van Duzer

Ruben Alberto Tommasi

Leslie Wighton McQuire

Paul David Greenspan

Scott Douglas Cowen

Felix Waldmeier

Hanspeter Nick

Michihiro Takai

Miyuki Horiuchi

Keigo Gohda

The invention relates to a compound of formula (1) in free form or in pharmaceutically acceptable salt form to pharmaceutical compositions comprising said compound and to the use of said compound in the treatment of heterotopic ossification and fibrodysplasia ossificans progressiva.

Aminopyridine derivatives and their use as selective ALK-2 inhibitors

The invention relates to a compound of formula (I) in free form or in pharmaceutically acceptable salt form to pharmaceutical compositions comprising said compound and to the use of said compound in the treatment of heterotopic ossification and fibrodysplasia ossificans progressiva.

The invention relates to a compound of formula (I) in free form or in pharmaceutically acceptable salt form (I) to pharmaceutical compositions comprising said compound and to the use of said compound in the treatment of heterotopic ossification and fibrodysplasia ossificans progressiva. 

The invention relates to combination comprising a pharmaceutically acceptable preparation of a compound of formula (I), or a pharmaceutically acceptable salt thereof, and a gallium and its use in diagnosis. The invention also pertains to the use of a compound of formula I or a pharmaceutically acceptable salt thereof, for the preparation of a medicament for the treatment of an excess iron overload in the human or animal body whereby said body is undergoing gallium scintigraphy and whereby the treatment removing said excess of iron is interrupted for a period of 2 to 10 days prior to the gallium scintigraphy and resumed after the gallium scintigraphy readings. 

Method of scintigraphy

The invention provides compounds of formula I or a pharmaceutically acceptable salt or ester thereof wherein the symbols have meaning as defined, which are inhibitors of cathepsin K and find use pharmaceutically for treatment of diseases and medical conditions in which cathepsin K is implicated, e.g. various disorders including inflammation, rheumatoid arthritis, osteoarthritis, osteoporosis and tumors.

Heteroaryl nitrile derivatives

The invention provides compounds of Formula (I) or a pharmaceutically acceptable salt or ester thereof wherein the symbols have meaning as defined, which are inhibitors of cathepsin K and find use pharmaceutically for treatment of diseases and medical conditions in which cathepsin K is implicated, e.g. various disorders including inflammation, rheumatoid arthritis, osteoarthritis, osteoporosis and tumors. 

Hetereoaryl nitrile derivatives

The invention provides compounds of Formula I or a pharmaceutically acceptable salt or ester thereof wherein the symbols have meaning as defined, which are inhibitors of cathepsin K and find use pharmaceutically for treatment of diseases and medical conditions in which cathepsin K is implicated, e.g. various disorders including inflammation, rheumatoid arthritis, osteoarthritis, osteoporosis and tumors. 

Pyrrolo pyrimidines as agents for the inhibition of cystein proteases

The present invention provides new 4-[3,5-bis-(2-hydroxy-phenyl)-[1,2,4]triazol-1-yl]-benzoic acid derivatives which can be used in the treatment of diseases which cause an excess of metal in the human or animal body or are caused by it. 

4-[3,5-bis-(2-hydroxy-phenyl)-[1,2,4]triazol-1-yl]-benzoic acid derivatives for treating an excess of metal in the body

Dipeptide nitriles

Growing community of inventors

Oberwil, Switzerland

Rene Lattmann